,51 Recently, several publications suggested optimization of risk stratifications of AML by incorporating additional genetic lesions.52, 53, 54, 55 The newly published risk classification of the European LeukemiaNet recommends mutational analysis of genes, including BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 as these alterations are associated with high-risk features and adverse prognosis.56 This evidence concerns the gene SRSF2 and acute myeloid leukemia.